newsfilter
← Earnings
Earnings Releases·

Kiniksa Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Q3 2026 total revenue reached $286.0 million, up from $180.9 million in Q3 2025, driven by ARCALYST net product revenue of $286.0 million; net income increased to $47.3 million from $18.4 million in the prior year period.
  • 2026 ARCALYST net product revenue guidance was raised to $1.045 billion – $1.050 billion, reflecting strong commercial execution and positioning the asset for blockbuster status.
  • The company maintains a robust financial position with $568.8 million in cash and no debt, supporting an operating plan expected to remain cash flow positive annually.
  • Future outlook includes KPL-387 pivotal Phase 3 data expected in H2 2027 with a target patient availability in 2028/2029, and a Phase 1 trial for KPL-1161 scheduled to initiate by end of 2026.
Company
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
Sector
Healthcare
Industry
Biotechnology